INmune Bio, Inc. (INMB) Misses Q1 EPS by 8c

INmune Bio, Inc. (NASDAQ: INMB) reported Q1 EPS of ($0.61), $0.08 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $14 thousand versus the consensus estimate of $43 thousand.

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance